| Literature DB >> 34836503 |
Ying Sheng1, Wen-Long Zheng2, Qi-Fang Shi3, Bing-Yu Zhang4, Guang-Yao Yang1.
Abstract
BACKGROUND: The purpose of this study was to retrospectively analyze clinical characteristics and prognostic risk factors of urosepsis patients admitted to two intensive care units in Shanghai, China.Entities:
Keywords: Clinical characteristics; Prognosis; Urinary tract infections; Urosepsis
Mesh:
Substances:
Year: 2021 PMID: 34836503 PMCID: PMC8627060 DOI: 10.1186/s12871-021-01520-5
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Fig. 1The flow diagram description for inclusion in the study population
Demographic and clinical data of the patients included in this study
| Total | Survival group | Death group | |||
|---|---|---|---|---|---|
| Age (years) | 72.02 ± 9.66 | 71.27 ± 9.68 | 76.00 ± 8.61 | 2.577 | 0.011 |
| Female (%) | 160 (79.21) | 138 (81.18) | 22 (68.75) | 2.525 | 0.112 |
| Shock(%) | 74 (36.63) | 52 (30.59) | 20 (62.50) | 11.956 | 0.001 |
| Surgical treatment(%) | 170 (84.16) | 146 (85.88) | 24 (75.00) | 2.392 | 0.122 |
| APACHE II score | 17.90 ± 5.16 | 16.75 ± 4.18 | 24.00 ± 5.59 | 8.487 | < 0.001 |
| SOFA score | 6.24 ± 3.78 | 5.49 ± 3.36 | 10.22 ± 3.37 | 7.284 | < 0.001 |
| Diabetes(%) | 114 (56.44) | 92 (54.12) | 22 (68.75) | 2.345 | 0.126 |
| Hypertension(%) | 100 (49.50) | 82 (48.24) | 18 (56.25) | 0.692 | 0.405 |
| COPD(%) | 20 (9.90) | 18 (10.59) | 2 (6.25) | 0.568 | 0.451 |
| Chronic heart disease(%) | 58 (28.71) | 52 (30.59) | 6 (18.75) | 1.844 | 0.174 |
| Chronic kidney disease(%) | 42 (20.79) | 28 (16.47) | 14 (43.75) | 12.169 | < 0.001 |
| Cerebrovascular disease(%) | 52 (25.74) | 40 (23.53) | 12 (37.50) | 2.750 | 0.097 |
| Long-term indwelling catheter (%) | 26 (12.87) | 20 (11.76) | 6 (18.75) | 1.172 | 0.279 |
| WBC(× 109/L) | 17.52 ± 8.79 | 16.94 ± 8.73 | 20.58 ± 8.60 | 2.170 | 0.031 |
| Hb(g/L) | 107.49 ± 13.09 | 108.33 + 12.70 | 103.06 ± 14.43 | 2.107 | 0.036 |
| Platelet(×109/L) | 140.55 ± 69.36 | 144.72 ± 67.92 | 118.38 ± 73.78 | 1.985 | 0.048 |
| CRP (mg/L) | 107.85 ± 61.32 | 107.25 ± 62.68 | 111.05 ± 54.32 | 0.321 | 0.748 |
| PCT (ng/mL) | 49.17 ± 58.05 | 43.85 ± 53.72 | 77.43 ± 71.67 | 3.065 | 0.002 |
| SCr (μmol/L) | 165.90 ± 148.94 | 148.86 ± 140.46 | 256.44 ± 161.96 | 3.877 | < 0.001 |
| TBil (μmol/L) | 12.64 ± 10.13 | 12.10 ± 8.14 | 15.47 ± 17.14 | 1.734 | 0.084 |
| Albumin (g/L) | 30.25 ± 3.08 | 30.56 ± 2.92 | 28.60 ± 3.41 | 3.388 | 0.001 |
| D-dimer (mg/L) | 6.36 ± 6.80 | 6.20 ± 7.23 | 7.25 ± 3.80 | 0.799 | 0.425 |
| Oxygenation index (mmHg) | 274.39 ± 79.71 | 281.87 ± 77.96 | 234.63 ± 78.25 | 3.143 | 0.002 |
| Lactate (mmol/L) | 3.66 ± 2.33 | 3.25 ± 1.98 | 5.83 ± 2.84 | 6.294 | < 0.001 |
| Mechanical ventilation(%) | 37 (18.3) | 25 (14.71) | 12 (37.50) | 9.352 | 0.002 |
| CRRT(%) | 26 (12.87) | 20 (11.76) | 6 (18.75) | 1.172 | 0.279 |
| ICU LOS (days) | 9.07 ± 2.66 | 9.17 ± 2.76 | 8.56 ± 2.00 | 1.176 | 0.241 |
| Hospital LOS (days) | 13.14 ± 4.40 | 13.77 ± 4.41 | 9.84 ± 2.44 | 4.882 | < 0.001 |
APACHE II Acute physiology and chronic health evaluation II, SOFA Sequential organ failure assessment, COPD Chronic obstructive pulmonary disorder, WBC White blood count, Hb Hemoglobin, CRP C-reactive protein, PCT Procalcitonin, SCr Serum creatinine, TBiL Total bilirubin; CRRT Continuous renal replacement therapy, LOS length of stay
Univariate analysis of variables associated with urosepsis prognosis
| OR | 95% CI | ||
|---|---|---|---|
| Age | 1.058 | 1.012–1.107 | 0.013 |
| Shock | 3.782 | 1.722–8.304 | 0.001 |
| APACHE II score | 1.307 | 1.196–1.428 | < 0.001 |
| SOFA score | 1.398 | 1.243–1.572 | < 0.001 |
| Chronic kidney disease(%) | 3.944 | 1.759–8.845 | 0.001 |
| WBC | 1.046 | 1.003–1.091 | 0.034 |
| Hb | 0.969 | 0.940–0998 | 0.039 |
| PCT (ng/mL) | 1.008 | 1.003–1.014 | 0.004 |
| SCr (μmol/L) | 1.004 | 1.001–1.006 | 0.003 |
| Albumin (g/L) | 0.805 | 0.704–0.919 | 0.001 |
| Oxygenation index (mmHg) | 0.991 | 0.985–0.997 | 0.003 |
| Lactate (mmol/L) | 1.501 | 1.268–1.777 | < 0.001 |
| Mechanical ventilation | 3.480 | 1.514–7.997 | 0.003 |
CI Confidence interval, APACHE II Acute physiology and chronic health evaluation II, SOFA Sequential organ failure assessment, WBC White blood count, PCT Procalcitonin, SCr Serum creatinine
Multivariate analysis of variables associated with urosepsis prognosis
| OR | 95% CI | ||
|---|---|---|---|
| Mechanical ventilation | 7.260 | 2.200–23.963 | 0.001 |
| APACHE II score | 1.321 | 1.184–1.473 | < 0.001 |
| Chronic kidney disease | 5.140 | 1.596–16.550 | 0.006 |
| Lactate | 1.258 | 1.037–1.527 | 0.020 |
CI Confidence interval, APACHE II Acute physiology and chronic health evaluation II
ROC curve analysis of prediction for prognosis in patients with urosepsis
| Variables | AUC | 95% CI | |
|---|---|---|---|
| Mechanical ventilation | 0.614 | 0.500–0.728 | 0.041 |
| APACHE II score | 0.858 | 0.799–0.918 | 0.000 |
| Chronic kidney disease | 0.636 | 0.523–0.750 | 0.014 |
| Lactate | 0.805 | 0.717–0.892 | 0.000 |
CI Confidence interval, APACHE II Acute physiology and chronic health evaluation II
Fig. 2ROC curve analysis of prediction for prognosis in patients with urosepsis. ROC receiver operating characteristic, APACHE II acute physiology and chronic health evaluation II
Distribution of pathogens isolated from urosepsis patients experiencing uroseptic shock
| Total ( | Urosepsis | Uroseptic shock( | |||
|---|---|---|---|---|---|
| 186 (92.08) | 112 (94.92) | 74 (88.10) | 3.129 | 0.077 | |
| | 74 (36.63) | 64 (54.24%) | 10 (11.90%) | 37.881 | <0.001 |
| | 86 (42.57) | 38 (32.20%) | 48 (57.14%) | 12.483 | <0.001 |
| | 10 (4.95) | 2 (1.69%) | 8 (9.52%) | 4.186 | 0.041 |
| | 8 (3.96) | 4 (3.39%) | 4 (4.76%) | 0.016 | 0.889 |
| | 4 (1.98) | 2 (1.69%) | 2 (2.38%) | 0.000 | 1.000 |
| | 2 (0.99) | 0 (0.00%) | 2 (2.38%) | NA | NA |
| | 2 (0.99) | 2 (1.69%) | 0 (0.00%) | NA | NA |
| 4 (1.98) | 2 (1.69%) | 2 (2.38%) | 0.000 | 1.000 | |
| | 4 (1.98) | 2 (1.69%) | 2 (2.38%) | 0.000 | 1.000 |
| 12 (5.94) | 4 (3.39%) | 8 (9.52%) | 2.298 | 0.130 | |
| | 8 (3.96) | 2 (1.69%) | 6 (7.14%) | 2.531 | 0.112 |
| | 2 (0.99) | 0 (0.00%) | 2 (2.38%) | NA | NA |
| | 2 (0.99) | 2 (1.69%) | 0 (0.00%) | NA | NA |
ESBLs Extended-spectrumβ-lactamases